InVivo adds New Jersey's Cooper Neurological as clinical site: 5 points

Written by Megan Wood | August 13, 2015 | Print  |

InVivo Therapeutics added Cooper Neurological Institute in Camden, N.J., as a new clinical site for its Neuro-Spinal Scaffold investigational study.

Here are five points:


1. The Neuro-Spinal Scaffold is used for acute spinal cord injury treatment.


2. Steven Yocom, DO, professor of neurosurgery and co-director of Cooper Neurological Institute is the principal investigator at the new site.


3. A total of 13 clinical sites are open for enrollment.


4. This is the first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold.


5. The FDA approved the pilot study and it is expected to capture preliminary safety and effectiveness data in five subjects with acute thoracic spinal cord injury.


"Our group has a particular interest in spinal trauma and spinal cord injury," said Dr. Yocom. "I'm excited that InVivo is approaching the significant unmet medical need in this field with such a novel technology."


More articles on devices:
Medtronic short interest drops 1.1%: 5 key notes
LDR launches 30-day public offering: 5 key notes
Histogenics reports Q2 $7.6M loss: 5 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers